ArticleProceedings of the ACM on programming languages2019
Seq: A High-Performance Language for Bioinformatics.
Article in Proceedings of the ACM on programming languages, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 17 citations in OpenAlex.
- Shechi: A Secure Distributed Computation Compiler Based on Multiparty Homomorphic Encryption.Proceedings. UNIX Security Symposium · 2025Article
- Sequre: a high-performance framework for secure multiparty computation enables biomedical data sharing.Genome biology · 2023Article
- Fast characterization of segmental duplication structure in multiple genome assemblies.Algorithms for molecular biology : AMB · 2022Article
- A Python-based programming language for high-performance computational genomics.Nature biotechnology · 2021Article
- Improved haplotype inference by exploiting long-range linking and allelic imbalance in RNA-seq datasets.Nature communications · 2020Article
- A constructive model for collective intelligence.National science review · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The scope and scale of biological data are increasing at an exponential rate, as technologies like next-generation sequencing are becoming radically cheaper and more prevalent. Over the last two decades, the cost of sequencing a genome has dropped from $100 million to nearly $100-a factor of over 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.